

# A statistical study on the formulation development of sustained release tablets for valsartan sodium

## Abstract

**Objective:** The purpose of the current research work was to study effect of formulation variables in a statistical way for the SR formulations of Valsartan sodium.

**Methods:** Valsartan sodium is an antihypertensive agent angiotensin-II receptor blocker belongs to BCS class-III agent. SR tablet formulations of Valsartan sodium were formulated using variable quantities of HPMCK100M and Xanthan Gum by direct compression method. quantities of polymers was chosen as independent variables,  $X_1$  and  $X_2$  respectively whereas, time required for dissolution 10%( $t_{10\%}$ ), 50%( $t_{50\%}$ ), 75%( $t_{75\%}$ ) and 90%( $t_{90\%}$ ) of drug from formulation were chosen as dependent variables. 9 formulations were prepared and evaluated for various pharmacopoeial tests.

**Results:** The results reveals that all formulations were found to be with in the acceptable limits and release rate profiles of all formulations were fitted to kinetic models. The statistical parameters were determined. Polynomial equations were developed for dependent variables. Validity of them was checked by countercheck formulations ( $C_1, C_2$ ). According to SUPAC guidelines, formulation ( $F_4$ ) containing mixture of 12% HPMCK100M and 16% Xanthan gum, was found to be identical formulation (dissimilarity factor  $f_1=1.763$ , similarity factor  $f_2=86.747$  & No significant difference,  $t=0.0478$ ) to marketed product (VALZAAR).

**Conclusion:** Formulation  $F_4$  follows First order kinetics, Non-Fickian Diffusion Anomalous Transport. ( $n=0.826$ ).

**Keywords:** valsartan sodium,  $3^2$  factorial design, sustained delivery, hpmck100m, xanthan gum, first order kinetics, anomalous transport

Volume 2 Issue 5 - 2018

Raghavendra Kumar Gunda,<sup>1</sup> Prasada Rao Manchineni,<sup>2</sup> Venkatachalam Thangavel<sup>3</sup>

<sup>1</sup>Department of Pharmaceutics, M.A.M College of Pharmacy, India

<sup>2</sup>Department of Pharmaceutical Analysis, M.A.M College of Pharmacy, India

<sup>3</sup>Department of Pharmaceutical Chemistry, JKKMMRF College of Pharmacy, India

**Correspondence:** Raghavendra Kumar Gunda, Assistant. Professor, Department of Pharmaceutics, M.A.M College of Pharmacy, Kesanupalli(V), Narasaraopet, Guntur(D.t), A.P. India-522601, Tel +91-9666705894, E-mail raghav.gunda@gmail.com

**Received:** October 21, 2018 | **Published:** October 29, 2018

## Introduction

Oral route is the extensively used mode of administration for both conventional delivery systems and novel drug delivery systems. Tablets are the most famous solid dosage forms sold in the market. For chronic Therapy, immediate release formulations are required to be administered in repetitive mode results patient non-compliance.<sup>1</sup> However, oral administration of majority of drugs facilitates hepatic first pass metabolism, results low systemic availability of active ingredient, shorter action and development of non-active or toxic metabolites.<sup>2</sup> The aim of developing SR formulations is to maintain sink conditions ( $C_{ss}$  levels for prolonged period). Systems such as modified release/timed release also similar to sustained drug delivery.<sup>3-5</sup> SR formulations shows reduction in frequency of administration in comparison with prompt release dosage forms.<sup>6</sup> SR formulations offers advantage over immediate release formulations by optimising characteristics of active ingredients. Polymers plays a key role in the release of drug from formulations. Polymers from natural sources are widely used in product development due to numerous advantages. Gums such as guar, xanthan, tragacanth, alginates, pectin etc. cellulose such as HPMC, HPC, CMC, SCMC extensively used for retarding property.

Formulations processed by Direct Compression (DC) technique, a simple approach because of Easier, rapid production, No degradative effects occurred during manufacturing, compliance.<sup>6</sup> The suitability of drug candidates for sustained release system based on biopharmaceutical, pharmacokinetic and pharmacodynamic properties of it.

## Drug profile and rationality for experimental design

The aim of present research work, stastical study of formulating SR formulation of Valsartan sodium.

Valsartan sodium, antihypertensive agent, angiotensin-II receptor blocker, belongs to BCS Class-III agent. It is used for the management of myocardial Infarction, congestive heart failure. The main problem associated with this drug is, its low bioavailability (20-25%), shorter  $t_{1/2}$ (6hr). conventional tablets should be taken 2-3times a day to attain  $C_{ss}$ . Administration of Valsartan sodium in a sustained release formulation would be more beneficial for the management of hypertension. Hence, to reduce dosing frequency, improve therapeutic efficacy, patient compliance once daily sustained release Valsartan sodium is desirable.<sup>7-13</sup> Formulating a dosage form for obtaining a desirable drug release with minimum heuristics is essential. RSM with polynomial equation based concept has been efficiently utilised for optimization process. Hence an attempt is made in current work to design SR tablet formulations of Valsartan sodium using HPMCK100M and Xanthan gum by using  $3^2$  Factorial design technique. The significant variables such as quantity of HPMCK100M and Xanthan gum and dependent variables, i.e.  $t_{10\%}$ ,  $t_{50\%}$ ,  $t_{75\%}$ ,  $t_{90\%}$  (Time taken for dissolution 10%,50%,75%,90% of drug respectively).<sup>14,15</sup>

## Materials and methods

Materials used in research work were procured from the various sources. Valsartan sodium was a gift sample from Meditech Pharma Ltd, Hyderabad, India. HPMCK100M, Xanthan gum, MCC and Lactose were procured from Loba Chemie Pvt.Ltd, Mumbai. Other

excipients such as magnesium stearate, Talc were procured from S.D. Fine Chem. Ltd., Mumbai.

### Design, development of valsartan sodium sustained release tablet formulations

$3^2$  factorial design, describe the proportion in which the independent variables amounts of HPMCK100M and Xanthan gum were used in current proposal. The time required for 10% ( $t_{10\%}$ ), 50% ( $t_{50\%}$ ), 75% ( $t_{75\%}$ ) and 90% ( $t_{90\%}$ ) dissolution were opted as dependent variables. Significance terms were chosen at 95% confidence interval ( $p < 0.05$ ) for resultant equations. Polynomial equations were developed for dependent variables in accordance with Linear step-wise backward Regression Analysis Technique. The 3 levels of factor  $X_1$  (HPMCK100M) at 8%, 12%, 16% concentrations. 3 levels of factor  $X_2$  (Xanthan gum) at 8%, 12%, 16% concentrations (%with respect to 250mg). nine formulations were designed and prepared using trail run combinations of the two factors i.e  $X_1$ ,  $X_2$  as per experimental design and evaluated to check the significance of combined effects of  $X_1$ ,  $X_2$  to select the best combination and to optimise.

### Manufacture of valsartan sodium sustained release tablet formulations

Valsartan sodium SR Tablets were obtained by utilising Direct Compression method. Composition of each Tablet was shown in Table 2. All ingredients required for formulation were collected and weighed accurately and passed through sieve no 40. They were subjected to polybag mixing for 10–15min to obtain a uniform powder blend. magnesium stearate was added to the powder blend and then again mix for 4–5min. Blend was subjected to compression by using tablet Minipress (8mm round punches and same hardness used for required number of tablets). Compressed tablets were evaluated as per official standards and unofficial tests. Tablets were packaged in air tight, light resistance and moisture proof containers.

**Table 2** Formulae for the preparation of valsartan sodium sustained release tablets

Name of ingredients	Quantity of ingredients per each tablet (mg)								
	F <sub>1</sub>	F <sub>2</sub>	F <sub>3</sub>	F <sub>4</sub>	F <sub>5</sub>	F <sub>6</sub>	F <sub>7</sub>	F <sub>8</sub>	F <sub>9</sub>
Valsartan sodium	80	80	80	80	80	80	80	80	80
Lactose	66	76	86	76	86	96	86	96	106
Microcrystalline Cellulose	20	20	20	20	20	20	20	20	20
HPMC K 100M	40	40	40	30	30	30	20	20	20
Xanthan Gum	40	30	20	40	30	20	40	30	20
Magnesium Stearate	2	2	2	2	2	2	2	2	2
Talc	2	2	2	2	2	2	2	2	2
Total Weight	250	250	250	250	250	250	250	250	250

### Evaluation of valsartan sodium sr tablet formulations

#### Mechanical strength

The Mechanical strength of the tablets was determined by diametric breakdown of tablet with the help of Monsanto/ Pfizer's Hardness Tester, results expressed in terms of kg/cm<sup>2</sup>.

#### Friability

This test was executed by using Roche friabilator. A sample of 20

### Experimental design

Experimental design used in experimentation for the optimization of release rate modifiers concentration such as, quantity of HPMCK100M was labelled as  $X_1$  and quantity of Xanthan gum was labelled as  $X_2$ . Formulation design was summarized in Table 1. 3 levels for the quantity of HPMCK100M were selected and coded as  $-1 = 8\%$ ,  $0 = 12\%$ ,  $+1 = 16\%$ . Three levels for the quantity of Xanthan gum were selected and coded as  $-1 = 8\%$ ,  $0 = 12\%$ ,  $+1 = 16\%$ . Formulae for all the factorial batches were given in Table 2.

**Table 1** Experimental design layout

Formulation code	$X_1$	$X_2$
F <sub>1</sub>	1	1
F <sub>2</sub>	1	0
F <sub>3</sub>	1	-1
F <sub>4</sub>	0	1
F <sub>5</sub>	0	0
F <sub>6</sub>	0	-1
F <sub>7</sub>	-1	1
F <sub>8</sub>	-1	0
F <sub>9</sub>	-1	-1
C <sub>1</sub>	-0.5	-0.5
C <sub>2</sub>	0.5	0.5

tablets are taken weighed (W) and dedusted in a drum for 4minutes at a speed of 25rpm or 100 free falls and weighed (W<sub>1</sub>) again. % friability was determined by using following formula. %weight loss should not be more than 0.8.

$$\text{Friability (\%)} = \left[ \frac{(W - W_1)}{W} \right] \times 100$$

#### Content uniformity

A sample of 20 tablets was chosen randomly & the % drug content

was determined, the tablets content should be in the range of  $100 \pm 15\%$  of the labelled amount can be considered as the test was passed.

### Assay

A sample of 20 tablets collected and subjected to pulverisation. powder equivalent to 80mg was dissolved in 1dL of phosphate buffer pH6.8, subjected to agitation to get more solubilisation. The solution was filtered through a  $0.45\mu$  membrane filter, diluted suitably and the absorbance of final solution was measured by using UV-Visible Spectrophotometer at 251nm by employing phosphate buffer pH6.8 as blank.

### Thickness

This test was performed by using vernier calipers by placing the tablet between two arms of the vernier calipers. Final result was recorded

### In-vitro drug release study

The *In vitro* drug release study was performed by using USP XXIII type-II dissolution test apparatus (Paddle type) using 900ml of 0.1 N HCl as dissolution medium for initial 2hours followed by phosphate buffer pH6.8 at 50rpm and temperature  $37 \pm 0.5^\circ\text{C}$  as standard set of conditions specified by monograph for SR Formulations. At predetermined time intervals, 5 ml of the samples were withdrawn by means of a syringe fitted with a pre-filter, the volume withdrawn at each interval was replaced with same quantity of fresh dissolution medium. The resultant samples were analyzed for the absorbance at 251nm using UV Visible spectrophotometer after appropriate dilutions. The determinations were performed in triplicate ( $n=3$ ).

### Kinetic modeling of drug release

The dissolution profile of formulations was fitted in to zero-order, first-order, Higuchi and Korsmeyer-peppas models to know the pattern, order of drug release and mechanism.<sup>5,16,17</sup>

## Results and discussion

SR Tablet formulations of Valsartan sodium were prepared and optimized by  $3^2$  factorial design in order to screen the best combination of different drug release rate modifiers, HPMCK100M, Xanthan gum and also to achieve objective of present research work. The 2 factorial variables utilized in the development of formulations are, quantities of HPMCK100M & Xanthan gum were opted as independent variables ( $X_1, X_2$ ), and *In vitro* dissolution characteristics such as  $t_{10\%}$ ,  $t_{50\%}$ ,  $t_{75\%}$

&  $t_{90\%}$  considered as dependent variables 9 formulations were deigned and formulated utilizing  $3^2$  factorial design and all the formulations containing 80mg of Valsartan sodium as dose. All the tablets were subjected to various official tests such as mean hardness, friability, drug content, mean thickness and results are summarised in Table 3. The hardness of tablets was found to be  $4.525 \pm 0.43 - 5.07 \pm 0.42 \text{ Kg/cm}^2$ . % Weight loss in for formulations  $< 0.445$ . Drug content factorial formulations was found to be within acceptable range only. *In vitro* drug release studies were done for factorial batches using 0.1N HCl for initial 2hours followed by phosphate buffer pH6.8 as a dissolution media at 50rpm and  $37 \pm 0.5^\circ\text{C}$ . The *In vitro* dissolution profiles of tablets were shown in Figure 1–4 (Kinetic Plots) and the Statistical values for kinetic models were tabulated in Table 4. % Cumulative Drug release for trial batches  $F_1 - F_9$  at 12Hr were found to be  $89.20 - 96.325\%$ . From the result it reveals that the rate of drug release was higher for batches containing Low level of  $X_1$  compared with others, due to High quantity of polymer results drug may have entrapped within a polymer matrix causing a decrease in release rate. Therefore, predicted release of drug can be resulted by manipulating the quantities of  $X_1, X_2$ . Formulation  $F_4$  containing 30mg of HPMCK100M, 40mg of Xanthan gum exhibited promising kinetic values ( $t_{10\%} = 0.384\text{h}$ ,  $t_{50\%} = 2.520\text{h}$ ,  $t_{75\%} = 5.039\text{h}$ ,  $t_{90\%} = 8.370\text{h}$ ). The variation in initial rapid release of drug is due to difference in the viscosity of the polymeric mixtures. As we know that viscosity of polymer is inversely proportional to the rate of drug release, variation in the viscosity is due the formation of thicker gel layer in formulation.<sup>18</sup> The *In vitro* drug release profile of Valsartan sodium trial runs was subjected to goodness of fit test by linear backward step-wise regression analysis according to kinetic/mathematical models to know the drug release mechanism. Kinetic plots shown in Figure 1–4. It was known that from the above results dissolution profile of most of batches follows First order kinetics with co-efficient of determination ( $R^2$ ) values above 0.972 (0.972–0.979). The values of  $r$  of factorial batches for Higuchi's kinetics was found to be 0.953–0.964, which confers that the data fitted well to Higuchi's square root of time equation confirming the release followed diffusion mechanism. Kinetic data also treated for Peppas equation, the slope ( $n$ ) values 0.626–0.887 that proves Non-Fickian diffusion mechanism (anomalous drug transport). Polynomial equations were derived for dependent variables by backward stepwise linear regression analysis with the help of PCP Disso software and kinetic plots were constructed by using SIGMAPLOT V13 software. Response surface morphology plots were shown in Figure 5–8 for  $t_{10\%}$ ,  $t_{50\%}$ ,  $t_{75\%}$  and  $t_{90\%}$  using  $X_1$  and  $X_2$  on both the axes respectively. The Kinetic parameters for factorial formulations  $F_1$  to  $F_9$  were shown in Table 5.

**Table 3** Post-compression parameters

S.No	Formulation code	Hardness (kg/cm <sup>2</sup> )	Thickness (mm)	Friability (%)	%Weight variation	Drug content(%)
1	$F_1$	$4.525 \pm 0.43$	$3.29 \pm 0.13$	$0.260 \pm 0.07$	$199.47 \pm 1.4$	$97.88 \pm 1.2$
2	$F_2$	$4.73 \pm 0.40$	$3.32 \pm 0.13$	$0.357 \pm 0.025$	$199.88 \pm 1.32$	$99.05 \pm 1.5$
3	$F_3$	$4.823 \pm 0.41$	$3.44 \pm 0.12$	$0.398 \pm 0.46$	$201.76 \pm 1.31$	$99.97 \pm 1.6$
4	$F_4$	$5.07 \pm 0.42$	$3.52 \pm 0.15$	$0.44 \pm 0.007$	$202.23 \pm 1.45$	$99.93 \pm 1.5$
5	$F_5$	$4.97 \pm 0.4$	$3.57 \pm 0.14$	$0.362 \pm 0.02$	$201.98 \pm 1.5$	$99.89 \pm 1.4$
6	$F_6$	$4.96 \pm 0.398$	$3.55 \pm 0.12$	$0.44 \pm 0.005$	$203.8 \pm 1.5$	$101.18 \pm 1.5$
7	$F_7$	$5.07 \pm 0.41$	$3.53 \pm 0.05$	$0.44 \pm 0.04$	$201.39 \pm 1.42$	$100.02 \pm 1.45$
8	$F_8$	$4.96 \pm 0.39$	$3.58 \pm 0.12$	$0.363 \pm 0.06$	$202.86 \pm 1.4$	$100.9 \pm 1.36$
9	$F_9$	$4.96 \pm 0.4$	$3.54 \pm 0.11$	$0.444 \pm 0.02$	$203.8 \pm 1.2$	$101.18 \pm 1.44$





Figure 1 Comparative zero order plots for F<sub>1</sub>–F<sub>9</sub>.Figure 2 Comparative first order plots for F<sub>1</sub>–F<sub>9</sub>.Figure 3 Comparative Higuchi plots for F<sub>1</sub>–F<sub>9</sub>.Figure 4 Comparative Korsmeyer–Peppas plots for F<sub>1</sub>–F<sub>9</sub>.

Table 4 Statistical parameters

S. No	Formulation code	Kinetic parameters											
		Zero order			First order			Higuchi			Korsmeyer–Peppas		
		a	b	r	a	b	r	a	b	r	a	b	r
1	F <sub>1</sub>	1.064	9.166	0.973	2.099	0.097	0.979	23.237	33.837	0.956	0.67	1.346	0.992
2	F <sub>2</sub>	0.309	9.339	0.972	2.108	0.107	0.982	22.744	34.71	0.961	0.719	1.317	0.99
3	F <sub>3</sub>	0.525	9.29	0.971	2.101	0.104	0.982	22.506	34.575	0.961	0.713	1.326	0.989
4	F <sub>4</sub>	0.466	9.554	0.971	2.129	0.119	0.975	22.954	35.426	0.958	0.826	1.196	0.992
5	F <sub>5</sub>	1.736	9.714	0.97	2.156	0.137	0.975	22.476	36.22	0.962	0.872	1.164	0.991
6	F <sub>6</sub>	1.896	9.707	0.97	2.153	0.136	0.974	22.338	36.213	0.962	0.887	1.145	0.991
7	F <sub>7</sub>	1.822	9.574	0.968	2.125	0.124	0.976	22.183	35.77	0.962	0.845	1.19	0.988
8	F <sub>8</sub>	3.092	9.735	0.965	2.154	0.143	0.976	21.705	36.564	0.965	0.888	1.16	0.986
9	F <sub>9</sub>	3.252	9.727	0.965	2.152	0.142	0.975	21.567	36.557	0.965	0.902	1.143	0.986

F<sub>1</sub> to F<sub>9</sub> are factorial formulations, r–correlation coefficient, a–Intercept, b–Slope.

**Table 5** Dissolution parameters of valsartan sodium Sr tablets

S. No	Formulation code	Kinetic parameters			
		$t_{10}\%$ (hrs)	$t_{50}\%$ (hrs)	$t_{75}\%$ (hrs)	$t_{90}\%$ (hrs)
1	F <sub>1</sub>	0.472	3.107	6.214	10.324
2	F <sub>2</sub>	0.428	2.818	5.636	9.364
3	F <sub>3</sub>	0.438	2.883	5.766	9.58
4	F <sub>4</sub>	0.383	2.519	5.038	8.371
5	F <sub>5</sub>	0.335	2.203	4.406	7.32
6	F <sub>6</sub>	0.335	2.205	4.41	7.328
7	F <sub>7</sub>	0.37	2.435	4.87	8.091
8	F <sub>8</sub>	0.321	2.11	4.22	7.011
9	F <sub>9</sub>	0.321	2.113	4.226	7.022

Polynomial equation for 3<sup>2</sup> full factorial designs was explained as follows

$$Y = b_0 + b_1X_1 + b_2X_2 + b_{12}X_1X_2 + b_{11}X_1^2 + b_{22}X_2^2 \dots$$

Where, Y is dependent variable,  $b_0$  is average response of 9 trails,  $b_1$  is estimated co-efficient for  $X_1$ . The main effects ( $X_1$  and  $X_2$ ) shows the mean result/ impact of changing one factor at a time from proximities of low to high value. The interaction term/ compatibility ( $X_1X_2$ ) represents how the response varies when two factors/variables are simultaneously changed.  $X_1^2$  and  $X_2^2$  are useful for evaluating non-linearity. Validity of developed equations was scrutinised by

designing 2 check point formulations of intermediate concentration ( $C_1$ ,  $C_2$ ).

The polynomial equations for dependant variables developed as follows,

$$Y_1 = 0.377 + 0.053X_1 + 0.0219X_2 - 0.004X_1X_2 + 0.0406X_1^2 + 0.02519X_2^2 \text{ (for } t_{10}\%)$$

$$Y_2 = 2.489 + 0.356X_1 + 0.144X_2 - 0.026X_1X_2 + 0.269X_1^2 + 0.171X_2^2 \text{ (for } t_{50}\%)$$

$$Y_3 = 4.980 + 0.721X_1 + 0.285X_2 - 0.051X_1X_2 + 0.540X_1^2 - 0.333X_2^2 \text{ (for } t_{75}\%)$$



$$Y_4 = 8.272 + 1.191X_1 + 0.485X_2 - 0.080X_1X_2 + 0.896X_1^2 + 0.552X_2^2 \text{ (for } t_{90}\%)$$

The +ve sign for co-efficient of  $X_1$  in  $Y_1$ ,  $Y_2$ ,  $Y_3$  and  $Y_4$  polynomials denotes that, as the quantity of HPMCK100M increases, Y value also increases. In other hand, the represents that both independent variables shows significant impact on dependent variables. From the results it can be concluded that, as the increase in quantity of the retardants leads to decrease in drug release rate and drug release pattern may be changed by appropriate chosen of independent variables. The Drug release kinetic parameters for predicted from the developed polynomial equations and those actual observed from experimental results are presented in Table 6.

The closeness of both values for dependant variables indicates validity of developed equations. The response surface plots were constructed to show the impact of independent variables on dependant variables. F<sub>4</sub> is compared with marketed product (VALZAAR) shows similarity factor ( $f_2$ ) 86.74712, difference factor ( $f_1$ ) 1.76296 (There is no significant difference in drug release because  $t_{cal}$  is <0.05).

**Table 6** Dissolution parameters for predicted and observed values for check point formulations

Formulation code	Predicted value				Actual observed value			
	$t_{10}\%$ (h)	$t_{50}\%$ (h)	$t_{75}\%$ (h)	$t_{90}\%$ (h)	$t_{10}\%$ (h)	$t_{50}\%$ (h)	$t_{75}\%$ (h)	$t_{90}\%$ (h)
C1	0.357	2.333	4.679	7.776	0.355	2.331	4.681	7.775
C2	0.432	2.843	5.687	9.444	0.433	2.842	5.685	9.441

**Figure 5** Response surface plots for  $t_{10}\%$ .**Figure 6** Response surface plots for  $t_{50}\%$ .






Figure 7 Response surface plots for  $t_{75}\%$ .




Figure 8 Response surface plots for  $t_{90}\%$ .

## Conclusion

The current research theme envisions the use of release retardants, HPMCK100M and Xanthan gum in the formulation development of sustained release tablets of Valsartan sodium with the help of  $3^2$  factorial statistical design technique. From the results it clears that the amount of polymer is inversely proportional to the rate of drug release. Combination of retardants used since there is no incompatibility with the drug which may be more favourable for obtaining desired prolonged release of the drug.  $F_4$  obeys Higuchi's square root law, drug release pattern mechanism was found to be Non-Fickian Diffusion (Anomalous Transport), First order release type. On the basis of kinetic parameters, the optimized formulation  $F_4$  may be used for the effective management of hypertension and to reduce the risk of Low ventricular Dysfunction, cardiovascular disease, Heart attack, stroke. This may improve the patient compliance by reducing the dosing frequency. We could be able to minimize the per oral cost of the Formulation.

## Acknowledgements

The author would like to thank the Management, Principal & Staff of M.A.M College of Pharmacy, Kesanupalli (v) Narasaraopet, Guntur (D.t), A.P., India for facilities granted for the successful completion research work.

## Conflict of interest

Authors declare that there is conflict of interest.

## References

1. Raghavendra Kumar Gunda, Suresh Kumar JN, Ajay Babu CH, et al. Formulation Development and Evaluation of Lamotrigine Sustained Release Tablets Using  $3^2$  Factorial Design. *Int J Pharm Sci Res.* 2015;6(4):1746–1752.
2. Raghavendra Kumar Gunda, Prasara Rao Manchineni, Dhachinamoorthi D. Design, development, and *in vitro* evaluation of sustained release tablet formulations of olmesartan medoxomil. *MOJ Drug Des Develop Ther.* 2018;2(3):165–170.
3. Bankar GS, Rhodes CT. *Modern Pharmaceutics*. 3<sup>rd</sup> ed. Marcel Dekker, editor. New York. 1996;668–669.
4. Lachmann L, Lieberman HA, Kanig JL. *The Theory & Practice of Industrial Pharmacy*. 3<sup>rd</sup> ed. Bombay. 1991;430.
5. Raghavendra Kumar Gunda, Formulation Development and Evaluation of Rosiglitazone Maleate Sustained Release Tablets Using  $3^2$  Factorial Design. *Int J Pharm Tech Res.* 2015;8(4):713–724.
6. Bankar GS, Rhodes CT. *Modern Pharmaceutics*. 4<sup>th</sup> ed. Marcel Dekker, editor. USA. 2003;503–505.
7. Anil kumar, Sujatha kumari M, Surekha K, et al. Formulation and evaluation of sustained release valsartan matrix tablets by using natural polymers. *IJPCBS.* 2012;2(2):146–150.
8. Ganesh Kumar G, Raghuvver P. Preparation and evaluation of sustained release matrix tablet of Valsartan using natural polymers. *Ind Amer J Pharm Res.* 2013;3(1):1310–1315.
9. Mohi Uddin. Development of sustained release tablet of valsartan. *WJPPS.* 2014;3(5):1196–1205.
10. Mahajan P, Mahajan SC, Mishra DK. Valsartan release from sustained release matrix tablet and effect of cellulose derivatives. *Int J of Pharm & Life Sci.* 2011;2(1):521–530.
11. Brahmaiah B, Sasikanth K, Sreekanth Nama P, et al. Formulation and Dissolution Study of Valsartan Immediate Release Tablets. *Int J Pharm Bio Res.* 2013;1(2):1–8.
12. Hingmire LP, Sakarkar DM. Formulation and evaluation of valsartan tablets using hydrophilic and hydrophobic polymer. *J Chem Pharm Sci.* 2013;6(4):254–260.
13. Dinesh Kumar Mishra, Dinesh Kumar Jain. Formulation and evaluation of valsartan sustained release matrix tablets. *Bull Pharm Res.* 2014;4(2):81–85.
14. Kharia AA, Hiremath SN, Singhai AK, et al. Design and Optimization of Floating Drug Delivery System of Acyclovir. *Indian Journal of Pharmaceutical Sciences.* 2010;72(5):599–606.
15. Raghavendra Kumar Gunda, Suresh Kumar JN, Chandan Kumar Brahma, et al. Design, Formulation and Evaluation of Atenolol Gastro Retentive Floating Tablets. *Asian Journal of Pharmaceutics.* 2015;9(4):S34–S42.
16. Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. *J Pharm Sci.* 1963;51:1145–1149.
17. Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. *Pharmaceutica Acta Helveticae.* 1985;60:110–111.
18. Dortunc B, Gunal N. Release of acetazolamide from swellable HPMC matrix tablets. *Drug Development and Industrial Pharmacy.* 1997;23:1245–1249.